May 30, 2017

List of private providers for lung cancer patients

We continue to receive enquiries from lung cancer patients with the PD-L1 expression about access to KEYTRUDA (Pembrolizumab). Because KEYTRUDA is not funded in New Zealand for all registered indications, patients may need to see a private provider to have this immunotherapy treatment prescribed. Some doctors working in public hospitals may be able to help […]